Get the Stockscreener App
0.878
2.37%
0.0203
After Hours:
.87
-0.008
-0.91%
Scienture Holdings Inc stock is traded at $0.878, with a volume of 71,820.
It is up +2.37% in the last 24 hours and down -56.32% over the past month.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
See More
Previous Close:
$0.8577
Open:
$0.847
24h Volume:
71,820
Relative Volume:
0.03
Market Cap:
$8.12M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.79%
1M Performance:
-56.32%
6M Performance:
-87.69%
1Y Performance:
+0.00%
1-Day Range:
$0.8214
$0.8975
1-Week Range:
$0.8035
$0.90
52-Week Range:
$0.69
$9.55
Scienture Holdings Inc Stock (SCNX) Company Profile
Name
Scienture Holdings Inc
Sector
Industry
Phone
(800) 261 0281
Address
2420 BRUNELLO TRACE, LUTZ
Compare SCNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.878 | 8.12M | 0 | 0 | 0 | 0.00 |
|
WBA
Walgreens Boots Alliance Inc
|
10.99 | 9.34B | 147.66B | -8.64B | -363.00M | -10.01 |
|
WGRX
Wellgistics Health Inc
|
4.17 | 190.64M | 0 | 0 | 0 | 0.00 |
|
HITI
High Tide Inc
|
2.35 | 180.49M | 376.07M | -22.41M | 18.73M | -0.298 |
|
PETS
Petmed Express Inc
|
3.37 | 62.80M | 270.52M | -6.08M | 17.42M | -0.2944 |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd
|
0.995 | 11.33M | 0 | 0 | 0 | 0.00 |
Scienture Holdings Inc Stock (SCNX) Latest News
Scienture Announces Manufacturing And Supply Chain Readiness For ArbliTM, (Losartan Potassium) Oral Suspension, 10Mg/Ml For A Target Product Launch In July 2025 - marketscreener.com
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - The Manila Times
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. | SCNX Stock News - GuruFocus
Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets - Stock Titan
Scienture Holdings Divests Subsidiaries to Tollo Health - MSN
Scienture Holdings divests subsidiaries for $5 million By Investing.com - Investing.com South Africa
Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M - TipRanks
Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million - MarketScreener
Scienture Announces The Divestiture Of Its Legacy Subsidiaries - MarketScreener
Scienture Holdings divests subsidiaries for $5 million - Investing.com
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - The Manila Times
Strategic Pivot: Scienture Sells Healthcare IT Units for $5M, Doubles Down on Specialty Pharma - Stock Titan
SCNX stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
SCNX stock touches 52-week low at $0.97 amid market challenges By Investing.com - Investing.com South Africa
Scienture Holdings gears up for specialty pharma launches - Investing.com
Scienture CEO says focused on execution, growth, expansion for years ahead - TipRanks
Scienture Holdings gears up for specialty pharma launches By Investing.com - Investing.com UK
Scienture Holdings, Inc. Issues Annual Letter to Shareholders - TradingView
Major Pharma Transformation: Scienture Reveals Two FDA-Approved Drugs and $480M+ Market Opportunity - Stock Titan
Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register
Scienture Bolsters Commercial Operations with New Leadership and Syneos Health Partnership - AInvest
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times
Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan
3 Reasons APG is Risky and 1 Stock to Buy Instead - The Globe and Mail
Scienture Holdings Announces FDA Approval for ArbliTM - TipRanks
Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Scienture Holdings announces draw on Equity Line of Credit - MSN
Scienture announces draaw on Equity Line of Credit - TipRanks
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times
Organovo Announces Reverse Stock Split - The Manila Times
FDA Approves Revolutionary Liquid Losartan: Scienture's Game-Changing Hypertension Treatment - StockTitan
Scienture announces U.S. FDA approval of NDA for SCN-102 - TipRanks
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
FDA Approves Losartan Potassium for Reduction in Risk of Stroke - Drug Topics
What's Going On With Scienture Shares Tuesday? - Benzinga
FDA Approves SCN-102, Liquid Oral Suspension Formulation of Losartan - Pharmacy Times
Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light - Stocks Telegraph
Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan - MarketScreener
SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Breakthrough FDA Approval: First-Ever Liquid Hypertension Drug Targets $1.5B Market - StockTitan
Billionaires Ray Dalio and Paul Tudor Jones Are Piling Into a Hard Asset That Has Trounced Nvidia This Year - The Globe and Mail
Q4 Earnings Outperformers: D.R. Horton (NYSE:DHI) And The Rest Of The Home Builders Stocks - The Globe and Mail
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Scienture Holdings Inc (SCNX) Stock Behavior Isn’t As Predictable As You Think - Stocks Register
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Scienture Holdings appoints new CFO, stockholders vote at annual meeting By Investing.com - Investing.com Australia
Scienture Holdings appoints new CFO, stockholders vote at annual meeting - Investing.com
Scienture Holdings Inc Stock (SCNX) Financials Data
There is no financial data for Scienture Holdings Inc (SCNX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.00%
2.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):